Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Flagship Biosciences appoints Gina Wallar, Ph.D., MPH as new Chief Commercial Officer


Flagship Biosciences Logo

Flagship is a company dedicated to the best science, and Dr. Wallar’s passions for both science and business make her the perfect choice for our CCO.

Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the appointment of Gina Wallar, Ph.D., MPH as their new Chief Commercial Officer. Gina is an accomplished business executive in the diagnostics and pharma services industry with 20 years’ experience leading international sales teams, managing people, and spearheading business development from a financial perspective.

“We are very excited to have Gina join the Flagship team. Gina brings over 20 years of experience in commercial, operational, and scientific expertise, having held leadership positions at several large, commercial organizations,” said CEO Trevor Johnson. “Flagship is a company dedicated to the best science, and her passions for both science and business make her the perfect choice for our CCO.”

Prior to joining Flagship Biosciences, Dr. Wallar acted as Senior Vice President for Fulgent Genetics where she led their sales and business development efforts. Prior to that, Dr. Wallar held numerous positions at Neogenomics Laboratories from 2014-2022, most recently having acted as their President of Pharma Services. She also held leadership roles in the Clinical Division and as Director of Scientific Affairs and Project Management. For 12 years (from 2002-2014), Dr. Wallar served as the Director for LabCorp Clinical Trials in Los Angeles, CA and oversaw PD-L1 testing, supporting the first companion diagnostic approval.

Dr. Wallar earned her PhD at UCLA in molecular epidemiology with her field of study on risk susceptibility polymorphisms in the cancer stem cell pathway. She has an MPH from Boston University in Epidemiology and Biostatistics. Past research interests have included risk factors for identifying susceptibility to cancer as well as molecular prognostic indicators of disease.

“This is a remarkable time to join the Flagship Biosciences team,” said Gina. “I look forward to advancing Flagship’s award-winning solutions and stellar customer service with a world-class commercial organization. We are poised for big things and I am thrilled to be a part of Flagship’s exciting next chapter.”

To learn more about Flagship Biosciences, please visit flagshipbio.com.

About Flagship Biosciences

Founded in 2009, Flagship Biosciences, Inc., is a technology-driven spatial biology and biomarker services company delivering the most accurate and informative data available. We are revolutionizing biomarker analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Our services and technology dramatically improve on the data and interpretation from traditional methods, eliminating variability associated with typical biomarker assessments, and bringing new insights to analysis results. We provide expert scientific consultation for every client. Our team interprets results, contextualizes biology, and identifies the best course for success. For more information, please visit flagshipbio.com and follow us on Twitter and LinkedIn.

Share article on social media or email:



Pacific Edge to Showcase Leading Biomarker Strategies for the Evaluation and Management of Bladder Cancer at SESAUA


Concluding DRIVE will not only validate Cxbladder in a Veteran’s cohort, but also double as the first clinical validation of Cxbladder Detect+ in any patient cohort.

Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today announces its key activities and highlights at the 87th Annual AUA Southeastern Section (SESAUA) meeting to be held March 15-18 in Amelia Island, Florida.

The SESAUA meeting is the largest of the AUA sectional meetings, hosting urologists and other urological experts from the nine southeastern US states, Panama, Puerto Rico and the US Virgin Islands. As a key theme at this year’s conference, discussion will include a focus on leading strategies for the evaluation and management of urologic oncology patients, including those with bladder cancer.

Taking the podium, Pacific Edge will host a Symposium, scheduled for 12pm EST Thursday March 16, on the current and future use of molecular biomarkers in the detection and surveillance of non-muscle invasive bladder cancer (NMIBC). The session, led by Pacific Edge VP of Medical Affairs, Dr. Tamer Aboushwareb, will feature a keynote address from Dr. Sia Daneshmand, Professor of Urology and Director Clinical Research at the Keck School of Medicine, USC, and will culminate in a panel discussion including Q&A from the audience.

Alongside the Symposium, Pacific Edge will lead a Principle Investigator Meeting for the DRIVE study – a study focused on Cxbladder validation in a veterans cohort across multiple VA sites for which it plans to conclude enrolment in 2023. With the objective being to support the streamlined completion of the study, trial coordinators will use the session to share successes and address challenges linked to recruitment. “Concluding DRIVE will not only validate Cxbladder in a Veteran’s cohort, but also double as the first clinical validation of Cxbladder Detect+ in any patient cohort,” says Dr. Aboushwareb. “Validation of Cxbladder Detect+ remains one of our most important commercial milestones as the company looks to seek coding, coverage and pricing in the coming months.”

Share article on social media or email:

Rare Cannabinoid Company Announces Special Offers on CBN Gummies, CBD…


Rare Cannabinoid Company announces March Sleep Awareness Month offers of free CBN gummies for sleep with purchases and special sales on pure CBN oil tinctures, CBN CBD oil blends, and Hawaiian Choice…

(PRWeb March 08, 2023)

Read the full story at https://www.prweb.com/releases/rare_cannabinoid_company_announces_special_offers_on_cbn_gummies_cbd_cbn_oils_for_sleep_awareness_month/prweb19215256.htm

SPI Pharma Becomes Regional Sole Distributor for ACTILLETS™ MCC Microcrystalline Cellulose Pellets, TAP® Tartaric Acid Pellets and Directly Compressible Ibuprofen DC100


SPI Pharma Logo

SPI Pharma

“The partnership between SPI Pharma, Inc and ingredientpharm, supports SPI’s strategy of adding high performance products to our portfolio, and combined with our formulation expertise, further enhances our solution offering to customers.” said Scott Thomson, CEO of SPI Pharma.

SPI Pharma, Inc. (SPI), a global leader in providing specialized solutions to the pharmaceutical industry, announces that it has received sole distribution rights for CELLETS® MCC pellets and TAP® tartaric acid pellets, from ingredientpharm. SPI also received the sole distribution rights to directly compressible Ibuprofen DC100. This agreement includes sole distribution rights for North America, Latin America, New Zealand, and Australia. SPI plans to distribute the MCC pellets as ACTILLETS™ MCC pellets in these regions.

Microcrystalline cellulose and tartaric acid pellets are used to create modified release drugs and multi-unit particulate systems (MUPS) when used as starter cores for drug layering and coating. ACTILLETS™ MCC pellets have low friability, high sphericity, and smooth surfaces for consistent coating. TAP® tartaric acid pellets can be used to improve the solubility of weakly basic pharmaceutical actives. Ibuprofen DC100 is a 100% active granule without addition of further excipients enabling simpler, more cost-effective Ibuprofen formulations.

SPI Pharma is excited to expand its portfolio of pharmaceutical excipients and API’s with the addition of these products. “This partnership supports SPI’s strategy of adding high performance products to our portfolio, and combined with our formulation expertise, further enhances our solution offering to customers.” said Scott Thomson, CEO of SPI Pharma.

About SPI Pharma, Inc.

SPI Pharma, headquartered in Wilmington, Delaware, USA, provides innovative solutions to global pharmaceutical and nutritional customers. Product lines include Antacid Actives, Excipients, Drug Delivery Systems, Taste-Masking, and Vaccine Adjuvants. SPI Pharma specializes in drug development services, having participated in over 60 commercially launched and marketed drugs globally. With its sites in the United States, France, and India, the company solves the most challenging formulation problems –– efficiently, cost-effectively, and with a focus on service.

About ingredientpharm

ingredientpharm is a brand name of ADD Advanced Drug Delivery Technologies Ltd, Pratteln, Switzerland. ingredientpharm provides innovative drug carriers by changing the physical properties of existing excipients. We offer our expertise and technology to enhance the performance of APIs – mainly in the field of taste masking but also for easier processing. We can support our customers with tailor-made developments.

Share article on social media or email:

Lab Alley Joins 37th Annual SXSW for Speaking Engagement


Fred will be part of a panel discussion titled “The Art of Letting Go: The Emotional Toll of Founders’ Exit Strategies”. “I am excited and honored to be invited to speak at such an iconic event like SXSW. I am dedicating my talk to my beautiful mom, Nelci Elabed, who passed away suddenly in my hometown of Cleveland on Feb 19, 2023. I am still heartbroken to lose my best friend. My mom was the best entrepreneur I have EVER been associated with!”, says Fred Elabed. The experience Fred had losing his mother lends well to the topic so many entrepreneurs struggle with, their exit strategy.

Fred will join Marcus Bowman from ClifftonLarsonAllen to discuss The Art of Letting Go; The Emotional Toll of Founders’ Exit Strategies. Founders are often prepared for the logistics of selling a business, but rarely prepared for the impact of the actual separation of a business they invested in so deeply.

This invitation to Fred Elabed by Inc. Magazine and Founders House to speak at SXSW 2023 in Austin, Texas reflects on Lab Alley’s continued success as the go-to chemical marketplace for essential chemicals to make a better world. Daily-use essential food and plant-based natural organic chemicals are being shipped to thousands of customers in growing industries such as Personal Care and Cosmetics, Food and Beverage, Pharmaceutical and Nutraceutical, Life Sciences, and other major industries.

This event is hosted by Inc Magazine and Founders House. https://events.inc.com/inc-founders-house-2023/2904416

Date: Friday, March 10, 2023

Time: 2:50pm – 3:30pm

Where:

Foxy’s Proper Pub

201 Brazos Street

Austin, Texas 78701

Register: https://events.inc.com/Inc-Founders-House-2023/begin

For more information, please visit LabAlley.com.

Share article on social media or email:

Accessible Remote Care Management Introduces DANA™ Brain Vital


Man sitting at desk video chatting a doctor

“DANA is the much needed platform for determining cognitive status of an individual. We believe DANA is a perfect fit for our ARCM and home health care clients.” says Aarif Dahod, CEO of Accessible Remote Care Management and Accessible Home Health Care.

Accessible Remote Care Management, a provider of remote chronic care management technology, has introduced cognitive monitoring through DANA™ Brain Vital. The partnership allows the company to offer its ARCM and home healthcare clients the option to receive simple, remote cognitive assessments. This service gives providers a tool that can objectively measure a patient’s cognitive function on a more frequent basis than other assessment tools. This is essential when patients are experiencing symptoms or side effects that affect cognition and providers want to quantify the positive or negative impact of a patient’s cognitive change.

DANA is the only FDA-cleared remote cognitive assessment platform. The Brain Vital data shows measurement of reaction time from the results of five-minute interactive responses. Results show how quickly the brain responds to a variety of external signals. Data is stored in a HIPAA compliant cloud-based location which can be accessed on either Android or IOS devices. The fees for the test are CMS and Veteran Administration reimbursable.

The potential for convenience in remote care has grown in recent years, allowing more innovations to be developed. DANA takes brain assessment and care to a higher level. This technology assesses patients as they recover from injury or maintain mental acuity while working with physicians from their own homes. DANA is effective for individuals diagnosed with PTSD, Dementia, TBI, AD/HD, medication management, and long-term brain injuries to aid in the treatment of long or short–term remote care.

Aarif Dahod, CEO of Accessible Remote Care Management and Accessible Home Health Care stated, “ARCM and other providers of remote monitoring have excellent success in managing chronic clinical conditions. DANA is the much needed platform for determining cognitive status of an individual. We believe DANA is a perfect fit for our ARCM and home health care clients.” He added, “Being able to conduct regular cognitive assessments within their home adds to our clients’ comfort level.”

Abby Thompson, CRO of DANA stated, “We are excited to partner with ARCM to offer in-home simple cognitive and psychological assessments with DANA Brain Vital,” and added, “Our goal is to be the standard in offering valid, objective cognitive data to practitioners so they can best evaluate how their treatment plans are affecting their patients’ cognitive function over time.”

About Accessible Remote Care Management and Accessible Home Health Care

Founded in 2001, Accessible Home Health Care provides compassionate home health care to support families and keep seniors safe in the homes they love. Accessible Home Health Care offers customizable in-home health care services. The home health care industry is in transition, and the demand is outpacing caregiver resources.

Thus, Accessible Remote Care Management was launched with the use of multiple innovative technology solutions to enhance patients’ experiences, reduce health care costs, and provide tools for caregivers to provide a higher level of care. For more information about Accessible Remote Care Management, visit https://www.accessiblerpm.com.

About DANA

DANA™ is an FDA-cleared suite of cognitive and psychological assessments that measures subtle and acute changes in cognitive resilience and speed to aid in assessing an individual’s medical or psychological state. It provides a wealth of data – from single glance top-level scores to intensively detailed trial-by-trial data – and gives an over-time, visual representation of a person’s cognitive development side-by-side with psychological test scores. For more information about DANA, visit https://danabrainvital.com/.

Share article on social media or email: